Core Viewpoint - 泰德医药's stock price increased over 9%, reaching a new high of 40.54 HKD, driven by positive market sentiment ahead of its upcoming board meeting to approve mid-term results [1] Company Summary - 泰德医药 is the third largest global player in the peptide-focused CRDMO market, holding a market share of 1.5% as of 2023, according to Frost & Sullivan [1] - The company offers a full-cycle service from early discovery, preclinical research, clinical development to commercial production [1] - The top two players in the global peptide-focused CRDMO market account for 23.8% of the market share, while the remaining participants are more fragmented, with the third to sixth largest players, including 泰德医药, each holding approximately 1% market share [1] Financial Performance - 泰德医药's revenue for the past few years has shown strong momentum, with figures of 351 million, 337 million, and 442 million CNY [1] - The company's diverse client base and global presence support its growth, with clients spanning over 50 countries [1] - Revenue distribution is as follows: 55% from the United States, 21.4% from mainland China, 7.1% from Japan, and 11% from Europe, indicating a well-diversified market presence that mitigates risks associated with reliance on a single market [1]

Core Viewpoint - 泰德医药将于2025年8月29日召开董事会会议，审议并通过截至2025年6月30日的中期业绩及其发布 [1] Company Summary - 泰德医药的董事会会议将专注于中期业绩的审议 [1] - 会议定于2025年8月29日召开，涉及的财务周期为截至2025年6月30日的六个月 [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 董事長兼執行董事 徐琪博士 香港，2025年8月15日 （股份代號：3880） 董事會會議召開日期 泰德醫藥（浙江）股份有限公司（「本公司」）董事會（「董事會」）謹此宣佈，董事會 會議將於2025年8月29日（星期五）召開，藉以（其中包括）審議及批准本公司及其 附屬公司截至2025年6月30日止六個月的中期業績及其刊發。 承董事會命 泰德醫藥（浙江）股份有限公司 Medtide Inc. 泰 德 醫 藥（ 浙 江 ）股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） 於本公告日期，本公司執行董事為徐琪博士、李湘博士、李湘莉女士、Cheng Tao 女士及李玲梅女士；本公司非執行董事為吳一暉先生；及本公司獨立非執行董事 為于常海博士、朱迅博士及夏心晟先生。 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 泰德醫藥（浙江）股份有限公司（「本公司」） 呈交日期: 2025年8月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03880 | 說明 | H股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 73,598,888 | RMB | | 1 | RMB | | 73,598,888 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 73,598,888 | RMB | | 1 | RMB | | 73,598,888 | 備註： 第 ...

Summary of Key Points Core Viewpoint - The Hong Kong Stock Exchange (HKEX) saw 11 companies submit applications for listing from June 30 to July 6, with no companies passing the listing hearing during this period. Additionally, 7 companies initiated their public offerings, and 5 new stocks were listed. Group 1: Companies Submitting Applications - Puxiang Health Holdings Limited is a leading provider of integrated medical and elderly care services in North China, ranking second in revenue among its peers and first in revenue growth from 2022 to 2024 [2] - Magnesium Health Technology Co., Ltd. focuses on innovative payment solutions for medical expenses, being the largest provider of innovative health insurance solutions in China by policy count [3] - Yangtuo Technology Inc. operates a trading and service platform for home care and nutrition products, holding a 10.1% market share in the low-tier market [4] - Xiamen Ruiwei Information Technology Co., Ltd. specializes in image intelligent analysis products and solutions, leveraging machine learning and computer vision technologies [5] - Zijin Gold International Limited is a leading global gold mining company, ranking ninth in gold reserves and eleventh in production as of 2024 [6] - EVE Energy Co., Ltd. is a leading lithium battery platform company, ranking first in China for consumer cylindrical battery shipments and second globally for energy storage battery shipments [7] - Zhejiang Yifei Intelligent Technology Co., Ltd. is a leading industrial robotics company in China, focusing on the light industry [8] - ChipMight Semiconductor Technology (Hangzhou) Co., Ltd. is a leading power semiconductor company, ranking second in the global OLED display PMIC market [9] - Beijing Tongrentang Medical Investment Co., Ltd. is the largest non-public Chinese medicine hospital group by outpatient and inpatient visits [11] - Shandong Linglong Tire Co., Ltd. is the largest OE tire manufacturer in China and the third largest globally [12] - Magnesium Holdings Limited is an innovative automotive technology company focused on AI-driven integrated domain control solutions [13] Group 2: Public Offerings and New Listings - Seven companies initiated their public offerings, including Anjii Foods, which had a subscription rate of 44.2 times for its public offering [14][15] - Other companies like Lens Technology and Fortior also initiated their public offerings with significant interest from cornerstone investors [16][19] - Five new stocks were listed, including Yunzhisheng, which saw a closing price increase of 44.59% on its first day [20][21][22][23] Group 3: Market Insights - The Hong Kong Stock Exchange raised over HKD 107 billion in the first half of 2025, with a 20% increase in the Hang Seng Index [24] - The biopharmaceutical sector has seen a resurgence, with 10 companies successfully listing in the first half of 2025, compared to only 12 for the entire previous year [25][26] - The total fundraising amount for the biopharmaceutical sector reached HKD 15.6 billion in the first half of 2025, indicating strong market interest [26][27]

Cloud Computing and AI - Alibaba Cloud will establish new data centers in Malaysia and the Philippines, expanding its global infrastructure to 29 regions and 90 availability zones. The third availability zone in Malaysia is now operational, while the second in the Philippines is set to launch in October 2023. This move aims to meet the growing demand for cloud computing and AI services overseas [1] Electric Vehicles - Polestar announced that its upcoming SUV model, Polestar 7, will be produced in a factory being built by Volvo Cars in Slovakia. This will be Polestar's first model manufactured in Europe, with plans to launch the vehicle in 2028 [2] Beverage Industry - Genki Forest's iced tea series has entered mainstream retail channels in Indonesia, marking its second product line to launch in the country after sparkling water. The brand has established a presence in over 30,000 retail outlets in Indonesia and has also entered 591 Costco stores in the U.S. and 109 in Canada [2] - The Chinese tea brand, Jasmine Milk Tea, reported that its first store in Los Angeles generated revenue of 4.195 million yuan in its first month, selling over 77,000 drinks and setting a sales record for the brand's overseas locations [3] Coffee Industry - Luckin Coffee opened two stores in Manhattan, New York, as part of its international expansion strategy. The stores launched with a promotional price of $1.99 per cup and feature a cashier-less self-service model to enhance the digital experience [4] Retail Expansion - Anta announced plans to open its first flagship store in the U.S. in Beverly Hills in September 2025, aiming to enhance its high-end brand image in the North American market [5] Media and Entertainment - iQIYI launched its Indonesian site in Jakarta, partnering with local telecom operator Telkomsel to enhance user experience through localized content and services [6] Manufacturing Expansion - BYD inaugurated its passenger car factory in Bahia, Brazil, with an investment of 5.5 billion reais (approximately 7.2 billion yuan), marking a significant step in its global strategy [7] - CRRC is expected to establish a new train manufacturing plant in Brazil, enhancing its competitiveness in the South American market [8] - Beijing Foton signed a memorandum with Saudi Arabia to build a commercial vehicle assembly plant, further expanding its global manufacturing footprint [9] Investment and Financing - Shenkepu Industrial completed a B+ round financing exceeding 100 million yuan, aimed at upgrading core technologies and expanding its international strategy [10] - Taited Pharmaceutical successfully listed on the Hong Kong Stock Exchange, with a market capitalization exceeding 4.3 billion HKD, focusing on peptide-related services [11] - Luxshare Precision announced plans for an H-share listing in Hong Kong, aiming to raise over $1 billion to support its global strategy and automotive business expansion [11] Hospitality Industry - Jin Jiang International Hotel submitted an IPO application to the Hong Kong Stock Exchange, aiming to enhance its overseas hotel business and digital transformation [11]

Core Viewpoint - 泰德医药 officially listed on the Hong Kong Stock Exchange on June 30, 2025, raising funds to expand production capacity and focusing on the GLP-1 pipeline development in response to increasing competition and regulatory challenges in the U.S. market [1][2][3] Group 1: Company Overview - 泰德医药 is a biopharmaceutical company based in Hangzhou, providing full-cycle services from early discovery to commercial production, primarily focusing on peptide NCE discovery and synthesis (CRO services) and peptide CMC development and commercial production (CRDMO services) [1][2] - The company has a project pipeline that includes 1,217 ongoing CRO projects and 332 ongoing CDMO projects, with a strategic focus on GLP-1 pipeline construction [1][3] - In 2023, 泰德医药 became the third largest global CRDMO focused on peptides, holding a market share of 1.5%, following Swiss leaders Bachem and PolyPeptide [1] Group 2: Financial Performance - 泰德医药's revenue for 2022, 2023, and projected 2024 are 350 million RMB, 330 million RMB, and 440 million RMB respectively, with net profits of 53.98 million RMB, 48.91 million RMB, and 59.17 million RMB [2] - The company plans to utilize 76.4% of the 4.11 billion HKD raised from the IPO to build or acquire production facilities in China and the U.S. to enhance production capacity [3] Group 3: Market Position and Strategy - 泰德医药's overseas revenue accounted for 78% in 2023, with the U.S. being the largest market, contributing 37.7%, 34.1%, and 55.0% of revenue from 2022 to 2024 [7][8] - The company aims to increase local production capacity in the U.S. to mitigate potential impacts from U.S. tariff policies, with plans to complete a facility in Rocklin, California, by the second half of 2025 [9] - The global peptide drug market is projected to grow significantly, with a market size of 38.9 billion USD in 2023 and a compound annual growth rate of 33.2% [3] Group 4: Industry Context - The biopharmaceutical industry in Hangzhou's 钱塘区 is rapidly developing, with 泰德医药 being the third listed company in the area in 2025, highlighting the region's focus on attracting high-quality biopharmaceutical enterprises [10] - The company is part of a broader trend where Chinese CXO firms are increasing local production capabilities in response to global market dynamics and regulatory challenges [9]

Core Viewpoint - The Hong Kong pharmaceutical sector is experiencing significant growth, particularly in innovative drugs, with many companies seeing their stock prices double [1]. Group 1: Market Dynamics - The listing of TIDE Pharmaceutical (03880.HK) on June 30 attracted considerable market attention, with a subscription rate of 301.15 times for public offerings and 2.43 times for international offerings [2]. - TIDE Pharmaceutical is positioned in a favorable market window, driven by two core market dynamics: the global capital market's shift towards Chinese technology assets and the upcoming results in China's innovative drug industry by 2025 [3][4]. Group 2: Industry Growth Potential - The global peptide drug market is projected to reach $261.2 billion by 2032, with a compound annual growth rate (CAGR) of 12.6% [7]. - In China, the GLP-1 drug market is expected to grow from $100 million in 2018 to $1.3 billion in 2023, with a CAGR of 65.3%, and further to $23.2 billion by 2032, with a CAGR of 37.3% [11]. - TIDE Pharmaceutical is strategically focusing on the GLP-1 sector, which is becoming a major trend in the pharmaceutical industry [7]. Group 3: Competitive Positioning - TIDE Pharmaceutical is recognized as the third-largest peptide CRDMO globally, with nine GLP-1 molecule development projects and partnerships with seven clients [15]. - The company is expanding its production capacity, with facilities in Hangzhou and the U.S., to meet the anticipated surge in market demand [16]. Group 4: Technological Advancements - TIDE Pharmaceutical has over 20 years of experience in the peptide CRDMO industry, with a strong team of experts and a wealth of knowledge in peptide drug design and synthesis [18]. - The company utilizes multiple proprietary technology platforms, including OmniPeptSynth™ and PeptiNuclide LinkTech™, to enhance its innovation capabilities [19][20]. - TIDE's long-term service capabilities have earned recognition from pharmaceutical companies, further solidifying its position in the peptide drug sector [21]. Group 5: Future Outlook - TIDE Pharmaceutical is well-positioned to benefit from the upcoming expiration of patents for major GLP-1 drugs, which will create significant demand for generic APIs [23]. - The company is also exploring opportunities in the oligonucleotide drug sector, indicating a broad market potential [23]. - Overall, TIDE Pharmaceutical's strategic positioning and technological expertise suggest strong long-term growth potential in the innovative drug market [22].

Core Viewpoint - The Hong Kong stock market is experiencing a surge in IPO activity, with multiple companies set to list in the coming days, indicating a robust market environment for new listings [1][3][18]. Group 1: Upcoming IPOs - On June 30, six companies announced their IPOs, with plans to list between June 30 and July 4, 2025 [1][3]. - The companies planning to list include Lens Technology, Fortior, Xunzhong Communication, Jizhi Jia, Dazhong Oral, and Shougang Longze, with Lens Technology and Fortior being A-share listed companies [1][3]. - Three companies, including Taide Pharmaceutical, Yunzhisheng, and IFBH, successfully listed on June 30, 2025, with Taide Pharmaceutical's share price set at 30.6 HKD [1][4]. Group 2: Financial Performance of Listed Companies - Yunzhisheng reported revenues of approximately 601 million RMB, 727 million RMB, and 939 million RMB for 2022, 2023, and 2024, respectively, with net losses of 375 million RMB, 376 million RMB, and 454 million RMB [4][6]. - Taide Pharmaceutical raised approximately 514 million HKD, with a net amount of about 429 million HKD after expenses, and secured two cornerstone investors contributing a total of 10 million USD [8]. - IFBH raised around 1.158 billion HKD, with a net amount of approximately 1.074 billion HKD, and is recognized as the second-largest coconut water beverage company globally [8]. Group 3: Market Trends and Future Outlook - The Hong Kong stock exchange has seen over 40 new listings in the first half of 2025, a significant increase compared to the same period in 2024, with total fundraising exceeding 100 billion HKD [17]. - The market is expected to remain active, with more companies preparing for IPOs, including those that have already submitted applications [17][18]. - The trend indicates a growing interest from A-share listed companies to enter the Hong Kong market, with over 70 companies submitting applications in June 2025 alone [17].

Core Viewpoint - 泰德医药 (Zhejiang Taide Pharmaceutical Co., Ltd.) has successfully listed on the Hong Kong Stock Exchange, with an initial trading price of 30.3 HKD and a closing price of 30.8 HKD, reflecting a slight increase of 0.65% on the first day of trading [1]. Summary by Relevant Sections IPO Details - The final offer price for the shares was set at 30.6 HKD, raising a total of 514.08 million HKD. After deducting estimated listing expenses of 85.31 million HKD, the net proceeds amounted to 428.77 million HKD [3][4]. Share Distribution - A total of 16,800,000 H-shares were issued, with an equal split of 8,400,000 shares allocated for public offering in Hong Kong and international offering [1]. Key Investors - The cornerstone investors for the IPO include Shiyao and Welight Capital [4]. Business Focus - The company primarily provides Contract Research Organization (CRO) services, focusing on peptide NCE discovery synthesis, and Contract Development and Manufacturing Organization (CDMO) services, which include peptide CMC development and commercial production. The services are mainly centered on providing Active Pharmaceutical Ingredients (API) rather than finished drugs [4]. Use of Proceeds - The funds raised will be utilized for expanding service capabilities and production capacity in the U.S. and China, increasing production capacity in China, establishing sales and after-sales service networks in more regions, and general corporate purposes [4]. Financial Performance - Projected revenues for 2022, 2023, and 2024 are 351 million RMB, 337 million RMB, and 442 million RMB, respectively. The net profits for the same years are expected to be 53.98 million RMB, 48.91 million RMB, and 59.17 million RMB [5][6].